Amendment in Response to Examiner Communication

AMENDMENTS TO THE CLAIMS

Docket No.: D0504.70009US00

Applicant has submitted a new complete claim set. This listing of claims will replace all prior versions and listings of claims in the application:

- 1-23. (Canceled)
- 24. (Currently Amended) A method of modulating an immune response in a subject, comprising:

administering to a subject in need of such immune modulation an amount of a compound effective to enhance the subject's immune response to an antigen, wherein the compound is of the formula:

$$R_1$$
 X X R_2 R_3

wherein,

R₁ is alkyl, aryl, or heterocyclyl cycloalkyl;

 R_2 is H, OH, alkyl, aryl, heterocyclyl, OR_3 , or $N(R_3)_{2}$;

R₃ is H, alkyl, aryl, or heterocyclyl phenyl, optionally substituted phenyl;

 R_4 is H, CN, halogen, CF_3 , CO_2R_3 , or $C(O)N(R_3)_2$:

X is S, SO₂, O, or NR₃; and

Y is S, O, or NR_3 .

- 25-28. (Canceled)
- 29. (Previously presented) The method of claim 24 wherein the subject is a subject having or at risk of having a cancer expressing a cancer antigen.

Application No. 10/585,216 Amendment dated October 3, 2011 Amendment in Response to Examiner Communication Docket No.: D0504.70009US00

30-44. (Canceled)

45. (Previously presented) The method of claim 24 wherein the subject is a subject having or at risk of having an infectious disease.

3

- 46-67. (Canceled)
- 68. (Currently amended) A method of enhancing MHC Class II catalyzed peptide exchange comprising contacting a cell bearing a MHC Class II molecule with a compound in the presence of a peptide that binds MHC class II, wherein the compound is of the formula:

wherein,

R₁ is alkyl, aryl, or heterocyclyl cycloalkyl;

 R_2 is H, OH, alkyl, aryl, heterocyclyl, OR_3 , or $N(R_3)_2$:

R₃ is H, alkyl, aryl, or heterocyclyl phenyl, optionally substituted phenyl;

 R_4 is H, CN, halogen, CF_3 , CO_2R_3 , or $C(O)N(R_3)_2$:

X is S, SO₂, O, or NR₃; and

Y is S, O, or NR_3 .

69-113. (Canceled)

114. (Currently amended) The method of claim 24, wherein

R₁ is alkyl, aryl, or heterocyclyl cycloalkyl;

Amendment in Response to Examiner Communication

 R_2 is H, OH, aryl, heterocyclyl, OR₃, or $N(R_3)_{2}$;

R₃ is aryl or heterocyclyl phenyl, optionally substituted phenyl;

 R_4 is H, CN, halogen, CF_3 , or $C(O)N(R_3)_{2}$;

X is S, SO₂, or O; and

Y is S or O.

115. (Currently amended) The method of claim 24, wherein

R₁ is alkyl, aryl, or heterocyclyl cycloalkyl;

 R_2 is H, OH, OR₃, or $N(R_3)_2$;

R₃ is aryl or heterocyclyl phenyl, optionally substituted phenyl;

 R_4 is H, CN, F, Cl, Br, or CF_{3} ;

X is S; and

Y is S.

116. (Previously presented) The method of claim 24, wherein the compound is represented by the formula:

Amendment dated October 3, 2011

Amendment in Response to Examiner Communication

5

- 117. (Previously presented) The method of claim 24, further comprising administering an antigen to the subject.
- 118. (Previously presented) The method of claim 117, wherein the antigen is a cancer antigen.
- 119. (Previously presented) The method of claim 117, wherein the antigen is a viral antigen, a bacterial antigen, a fungal antigen or a parasitic antigen.
- 120. (Currently amended) The method of claim 68, wherein

R₁ is alkyl, aryl, or heterocyclyl cycloalkyl;

 R_2 is H, OH, aryl, heterocyclyl, OR₃, or $N(R_3)_{2}$:

R₃ is aryl or heterocyclyl phenyl, optionally substituted phenyl;

 R_4 is H, CN, halogen, CF_3 , or $C(O)N(R_3)_2$;

X is S, SO_2 , or O; and

Y is S or O.

121. (Currently amended) The method of claim 68, wherein

Docket No.: D0504.70009US00

R₁ is alkyl, aryl, or heterocyclyl cycloalkyl;

 R_2 is H, OH, OR₃, or $N(R_3)_{2}$;

R₃ is aryl or heterocyclyl phenyl, optionally substituted phenyl;

R₄ is H, CN, F, Cl, Br, or CF₃:

X is S; and

Y is S.

122. (Previously presented) The method of claim 68, wherein the compound is represented by the formula:

- 123. (Currently amended) The method of claim 68, further comprising administering contacting the cell with an antigen to the subject.
- 124. (Previously presented) The method of claim 123, wherein the antigen is a cancer antigen.
- 125. (Previously presented) The method of claim 123, wherein the antigen is a viral antigen, a bacterial antigen, a fungal antigen or a parasitic antigen.